Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
25.17 x 200 25.21 x 900
Post-market by (Cboe BZX)
25.21 -0.34 (-1.33%) 03/26/25 [NYSE]
25.17 x 200 25.21 x 900
Post-market 25.20 -0.01 (-0.04%) 19:59 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
25.13
Day High
25.65
Open 25.52
Previous Close 25.55 25.55
Volume 49,578,800 49,578,800
Avg Vol 57,721,391 57,721,391
Stochastic %K 14.71% 14.71%
Weighted Alpha -11.53 -11.53
5-Day Change -1.00 (-3.82%) -1.00 (-3.82%)
52-Week Range 24.48 - 31.54 24.48 - 31.54
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,905,664
  • Shares Outstanding, K 5,671,455
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 17,697 M
  • EBITDA $ 24,710 M
  • 60-Month Beta 0.61
  • Price/Sales 2.33
  • Price/Cash Flow 5.99
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 26.07% ( +0.89%)
  • Historical Volatility 17.97%
  • IV Percentile 60%
  • IV Rank 54.40%
  • IV High 32.70% on 04/12/24
  • IV Low 18.16% on 05/13/24
  • Put/Call Vol Ratio 1.17
  • Today's Volume 216,208
  • Volume Avg (30-Day) 147,441
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 2,953,834
  • Open Int (30-Day) 3,011,517

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.67
  • Number of Estimates 6
  • High Estimate 0.81
  • Low Estimate 0.54
  • Prior Year 0.82
  • Growth Rate Est. (year over year) -18.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.13 +0.34%
on 03/26/25
Period Open: 26.42
27.24 -7.45%
on 03/10/25
-1.21 (-4.58%)
since 02/26/25
3-Month
25.13 +0.34%
on 03/26/25
Period Open: 26.56
27.57 -8.56%
on 01/07/25
-1.35 (-5.08%)
since 12/26/24
52-Week
24.48 +2.98%
on 11/15/24
Period Open: 27.59
31.54 -20.07%
on 07/30/24
-2.38 (-8.63%)
since 03/26/24

Most Recent Stories

More News
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

/CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is...

PFE : 25.21 (-1.33%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 6.1200 (-3.47%)
NVO : 71.73 (-2.54%)
NVS : 110.14 (-0.22%)
ABBV : 201.30 (-0.02%)
PFE : 25.21 (-1.33%)
Nasdaq Correction: Was It a Mistake to Add Nvidia, Amazon, and Salesforce to The Dow Jones Industrial Average?

The Dow Jones Industrial Average (DJINDICES: ^DJI) has changed a lot in recent years. In 2020, Salesforce, Amgen , and Honeywell International replaced ExxonMobil , Pfizer , and RTX , respectively, and...

NVDA : 113.76 (-5.74%)
$NASX : 17,899.01 (-2.04%)
HON : 213.12 (+0.47%)
$SPX : 5,712.20 (-1.12%)
PFE : 25.21 (-1.33%)
COMP : 9.39 (-0.42%)
INTC : 23.42 (-3.22%)
XOM : 118.27 (+1.44%)
WBA : 11.10 (-0.18%)
$DOWI : 42,454.79 (-0.31%)
AMZN : 201.13 (-2.23%)
CRM : 280.99 (-2.64%)
Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day

For Immediate ReleaseChicago, IL – March 25, 2025 – Zacks Equity Research shares Broadcom AVGO, as the Bull of the Day and Crown Castle CCI as the Bear of the Day. In addition, Zacks Equity Research...

AVGO : 179.27 (-4.78%)
CCI : 101.09 (+0.64%)
PFE : 25.21 (-1.33%)
Stock market today: Wall Street gains ground after shaking off four-week losing streak

Stocks closed broadly higher as Wall Street navigates through the uncertainty of a trade war

NVDA : 113.76 (-5.74%)
AZEK : 48.83 (-0.39%)
AAPL : 221.53 (-0.99%)
$SPX : 5,712.20 (-1.12%)
MU : 92.13 (-2.18%)
QXO : 13.56 (-2.16%)
$IUXX : 19,916.99 (-1.83%)
PFE : 25.21 (-1.33%)
MSFT : 389.97 (-1.31%)
BECN : 123.84 (+0.03%)
TSLA : 272.06 (-5.58%)
QCOM : 158.39 (-1.10%)
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren’t in bad shape either. So, is it the right time to bet...

PFE : 25.21 (-1.33%)
J&J to Invest $55B in United States to Boost Manufacturing, R&D

J&J JNJ announced plans to invest more than $55 billion in the United States over the next four years to boost manufacturing, R&D and technology in the country.  This represents a 25% increase in investment compared...

JNJ : 161.72 (+0.43%)
LLY : 826.76 (-3.00%)
PFE : 25.21 (-1.33%)
China's premier says US relations at 'an important juncture' during meeting with pro-Trump senator

Chinese Premier Li Qiang says Beijing and Washington should choose dialogue instead of confrontation

QCOM : 158.39 (-1.10%)
FDX : 243.67 (+1.08%)
PFE : 25.21 (-1.33%)
BA : 178.55 (-2.21%)
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.

ALT : 5.59 (-5.09%)
MRNA : 31.48 (-7.00%)
PFE : 25.21 (-1.33%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 72.72 (-0.45%)
JNJ : 161.72 (+0.43%)
NVS : 110.14 (-0.22%)
PFE : 25.21 (-1.33%)
SNY : 54.50 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.06
2nd Resistance Point 25.85
1st Resistance Point 25.53
Last Price 25.21
1st Support Level 25.01
2nd Support Level 24.80
3rd Support Level 24.48

See More

52-Week High 31.54
Fibonacci 61.8% 28.84
Fibonacci 50% 28.01
Fibonacci 38.2% 27.18
Last Price 25.21
52-Week Low 24.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies